Abir Kumar Panda

Abir Kumar Panda

Auto-generated profile, based on publicly available information

Abir Kumar Panda

Division of Molecular Medicine, Bose Institute, P-1/12, CIT Scheme VII M, Kolkata, 700054, India

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2017 in Journal of Experimental Pharmacology
Verified
Journal Article
Open access
PDF file
APAbir Kumar Panda
Abir Kumar Panda
DCDwaipayan Chakraborty
Dwaipayan Chakraborty
ISIrene Sarkar
Irene Sarkar
TKTila Khan
Tila Khan
GSGaurisankar Sa
Gaurisankar Sa
Natural compounds obtained from plants are capable of garnering considerable attention from the scientific community, primarily due to their ability to check and prevent the onset and progress of cancer. These natural compounds are primarily used due to their nontoxic nature and the fewer side effects they cause compared to chemotherapeutic drugs. Furthermore, such natural products perform even better when given as an adjuvant along with traditional chemotherapeutic drugs, thereby enhancing the potential of chemotherapeutics and simultaneously reducing their undesired side effects. Curcumin, a naturally occurring polyphenol compound found in the plant Curcuma longa, is used as an Indian spice. It regulates not only the various pathways of the immune system, cell cycle checkpoints, apoptosis, and antioxidant response but also numerous intracellular targets, including pathways and protein molecules controlling tumor progression. Many recent studies conducted by major research groups around the globe suggest the use of curcumin as a chemopreventive adjuvant molecule to maximize and minimize the desired effects and side effects of chemotherapeutic drugs. However, low bioavailability of a curcumin molecule is the primary challenge encountered in adjuvant therapy. This review explores different therapeutic interactions of curcumin along with its targeted pathways and molecules that are involved in the regulation of onset and progression of different types of cancers, cancer treatment, and the strategies to overcome bioavailability issues and new targets of curcumin in the ever-growing field of cancer.

12 October 2015 in Cell Division
Verified
Journal Article
Open access
SBSayantan Bose
Sayantan Bose
APAbir Kumar Panda
Abir Kumar Panda
SMShravanti Mukherjee
Shravanti Mukherjee
GSGaurisankar Sa
Gaurisankar Sa
Cell Division is an open access journal that allows the cell biology and cancer research communities to come together and focus on cross-sectional research ...

1 December 2013 in Immunity
Verified
Journal Article
Closed access
DHDewan Md Sakib Hossain
Dewan Md Sakib Hossain
APAbir K. Panda
Abir K. Panda
AMArgha Manna
Argha Manna
SMSuchismita Mohanty
Suchismita Mohanty
PBPushpak Bhattacharjee
Pushpak Bhattacharjee
GSGaurisankar Sa
Gaurisankar Sa

9 May 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SCSreeparna Chakraborty
Sreeparna Chakraborty
APAbir K. Panda
Abir K. Panda
SBSayantan Bose
Sayantan Bose
DRDia Roy
Dia Roy
KKKirti Kajal
Kirti Kajal
GSGaurisankar Sa
Gaurisankar Sa
T-regulatory cells are an upsurge in the tumor microenvironment and induce immune-evasion. CD4+ Treg cells are well characterized whereas the role of CD8+ Tregs in cancer has recently started to crease attention. Here, we report an augmentation CD8+FOXP3+ Tregs in breast tumor microenvironment. FOXP3, the lineage-specific transcription factor, is a dominant regulator of Treg cell development and function. FOXP3 is induced preferentially by divergent signaling in CD4+ Treg cells. But how FOXP3 is induced and maintained in tumor-CD8+ Tregs is the Cinderella of the investigation. We observed that RUNX3, a CD8+ lineage-specific transcription factor, binds at the FOXP3-promoter to induce its transcription. In addition to promoter activation, involvement of cis-elements CNS1 and CNS2 in the transcriptional regulation of FOXP3 was also evident in these cells. SMAD3 binds to CNS1 region and acts as transcription inducer, whereas GATA3 plays a temporal role in the FOXP3 transcription by differential chromatin modification in CNS regions. In CNS1 region, GATA3 acts as a repressor for FOXP3 in naïve CD8+ T cells. Whereas in CD8+ Tregs, GATA3 binds directly at CNS2 region and persuaded the maintenance of FOXP3. Therefore, the intervention of these concerted transcriptional machinery may have a therapeutic potential in immunotherapy of cancer.

9 March 2015 in Immunology
Verified
Journal Article
Closed access
PDF file
DHDewan Md Sakib Hossain
Dewan Md Sakib Hossain
APAbir K. Panda
Abir K. Panda
SCSreeparna Chakrabarty
Sreeparna Chakrabarty
PBPushpak Bhattacharjee
Pushpak Bhattacharjee
KKKirti Kajal
Kirti Kajal
GSGaurisankar Sa
Gaurisankar Sa

7 September 2016 in Scientific Reports
Verified
Journal Article
Open access
TSTaniya Saha
Taniya Saha
DGDeblina Guha
Deblina Guha
AMArgha Manna
Argha Manna
APAbir Kumar Panda
Abir Kumar Panda
JBJyotsna Bhat
Jyotsna Bhat
GSGaurisankar Sa
Gaurisankar Sa
P53 preserves genomic integrity by restricting anomaly at the gene level. Till date, limited information is available for cytosol to nuclear shuttling of p53; except microtubule-based trafficking route, which utilizes minus-end directed motor dynein. The present study suggests that monomeric actin (G-actin) guides p53 traffic towards the nucleus. Histidine-tag pull-down assay using purified p53(1–393)-His and G-actin confirms direct physical association between p53 and monomeric G-actin. Co-immunoprecipitation data supports the same. Confocal imaging explores intense perinuclear colocalization between p53 and G-actin. To address atomistic details of the complex, constraint-based docked model of p53:G-actin complex was generated based on crystal structures. MD simulation reveals that p53 DNA-binding domain arrests very well the G-actin protein. Docking benchmark studies have been carried out for a known crystal structure, 1YCS (complex between p53DBD and BP2), which validates the docking protocol we adopted. Co-immunoprecipitation study using “hot-spot” p53 mutants suggested reduced G-actin association with cancer-associated p53 conformational mutants (R175H and R249S). Considering these findings, we hypothesized that point mutation in p53 structure, which diminishes p53:G-actin complexation results in mutant p53 altered subcellular localization. Our model suggests p53Arg249 form polar-contact with Arg357 of G-actin, which upon mutation, destabilizes p53:G-actin interaction and results in cytoplasmic retention of p53R249S.